Sign In
Last checked at 
8 Jan 2018 07:00
8 January 2018
Avacta Group plc
("Avacta", "the Group" or "the Company")
Capital Markets Day Notification
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, today announces that it will host a Capital Markets Day for financial analysts and institutional investors on Wednesday, 7 February 2018 from 2pm to 4pm at finnCap's offices, 60 New Broad St, London, EC2M 1JJ.
The event will begin with a non-technical corporate update by Alastair Smith, Chief Executive Officer on strategy, key technical milestones and value inflection points and emerging themes within the business.
Following this update there will also be an opportunity to speak with other members of the Senior Management Team, whilst refreshments are served.
No new material information will be disclosed during the event.
If you would like to attend, please contact investorevents@avacta.com.
The presentation materials will be made available on the Group's website www.avacta.com
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking
WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang
| Tel: +44 (0) 207 220 0500 www.finncap.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Zyme Communications (Trade and Regional Media) Katie Odgaard
Yellow Jersey PR (Financial Media and IR) Sarah Hollins | Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com
Tel: +44 (0)7764 947137 avacta@yellowjerseypr.com
|
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
Follow the stocks
